β-lactam antibiotics remain a cornerstone of therapy against serious bacterial infections. However, standard dosing approaches fail to account for the complexity of critically ill patients. Significant PK variability in the ICU leads to inadequate exposure and treatment failures. 

Join Marc H. Scheetz, PharmD, MSc, FCCP, FCP and Will Musick, PharmD, BCIDP for a free webinar on October 25^th at 1:00pm ET to discuss:

• The growing threat of resistance and PK/PD principles for β-lactam optimization
• Evidence for exposure variability and individualized TDM
• Patient cases showing model-informed precision dosing in action
• Practical approaches to integrating pharmacokinetics and achieving clinical targets
• OPAT transitions and maintaining efficacy from hospital to home

Clinicians will leave empowered to elevate patient care through personalized β-lactam dosing. By considering each patient’s unique profile, precision strategies can improve outcomes, reduce resistance, and ensure therapy is optimized. This webinar provides you the tools to advance antibiotic stewardship.

Webinar objectives:

Part 1:

• Review the evidence that β-lactam pharmacokinetics demonstrate high interpatient variability in critically ill patients.
• Provide an overview of therapeutic drug monitoring and how it enables individualized precision dosing.
• Explore why TDM for β-lactams is underutilized in the US and strategies to increase adoption.

Part 2, patient cases:

• Discuss an approach to balancing efficacy and toxicity when using combination β-lactam therapy 
• Evaluate individualized precision dosing considerations for patients with borderline renal function through a case of piperacillin/tazobactam 
• Examine outpatient parenteral antibiotic therapy (OPAT) transitions and strategies to optimize continued efficacy through a case example of once-daily meropenem 

Meet the panelists

Marc H. Scheetz, PharmD, MSc, FCCP, FCP

Dr. Marc Scheetz is a Professor at Midwestern University in the Chicago College of Pharmacy, holds a joint appointment in the Department of Pharmacology, College of Graduate Studies, & is the Director of the Pharmacometric Center of Excellence at Midwestern University. He practices clinically as an ID pharmacist at Northwestern Memorial Hospital & serves as the Director for the Post-Doctoral Fellowship Program in Infectious Diseases Pharmacotherapy. He has authored over 190 original research manuscripts & review articles in the area of anti-infective pharmacokinetics & pharmacodynamics & serves as a reviewer for several journals. His primary research interest lies in the interface of the pharmacokinetic/pharmacodynamic interaction. He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases & identifying optimal exposures against the backdrop of toxicity. Dr. Scheetz attained a Doctorate of Pharmacy from Butler University, a Masters of Science in Clinical Investigation degree at Northwestern University, & completed his pharmacy practice residency & an ID fellowship at Northwestern Memorial Hospital.

Will Musick, PharmD, BCIDP

Dr. Musick is Infectious Diseases Clinical Specialist at Houston Methodist Hospital (HMH) in Houston,TX. He focuses on the Solid-Organ Transplant and Critically Ill populations. He developed and directs the PGY2 Infectious Diseases residency program at HMH and holds adjunct faculty appointments to the University of Houston College of Pharmacy and the University of Texas College of Pharmacy. His professional interests include teaching/training residents and students and researching atypical infections and CMV in the solid-organ transplant population.

Can’t make it on October 25th?

Don’t worry – we’ve got you covered! Register now and we will send you a link to watch the recording in your own time.